Literature DB >> 19568281

Everolimus.

Michael B Atkins1, Uma Yasothan, Peter Kirkpatrick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19568281     DOI： 10.1038/nrd2924

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  9 in total

Review 1.  Renal-cell carcinoma.

Authors:  Herbert T Cohen; Francis J McGovern
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

2.  Chemical modification of rapamycin: the discovery of SDZ RAD.

Authors:  R Sedrani; S Cottens; J Kallen; W Schuler
Journal:  Transplant Proc       Date:  1998-08       Impact factor: 1.066

Review 3.  Current development of mTOR inhibitors as anticancer agents.

Authors:  Sandrine Faivre; Guido Kroemer; Eric Raymond
Journal:  Nat Rev Drug Discov       Date:  2006-08       Impact factor: 84.694

4.  SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo.

Authors:  W Schuler; R Sedrani; S Cottens; B Häberlin; M Schulz; H J Schuurman; G Zenke; H G Zerwes; M H Schreier
Journal:  Transplantation       Date:  1997-07-15       Impact factor: 4.939

5.  Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference.

Authors:  Michael B Atkins; Ronald M Bukowski; Bernard J Escudier; Robert A Figlin; Gary H Hudes; William G Kaelin; W Marston Linehan; David F McDermott; James W Mier; Ivan Pedrosa; Brian I Rini; Sabina Signoretti; Jeffrey A Sosman; Bin Tean Teh; Christopher G Wood; Amado J Zurita; Laura King
Journal:  Cancer       Date:  2009-05-15       Impact factor: 6.860

Review 6.  Recent progress in the management of advanced renal cell carcinoma.

Authors:  Jorge A Garcia; Brian I Rini
Journal:  CA Cancer J Clin       Date:  2007 Mar-Apr       Impact factor: 508.702

7.  mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.

Authors:  Heidi A Lane; Jeanette M Wood; Paul M J McSheehy; Peter R Allegrini; Anne Boulay; Joseph Brueggen; Amanda Littlewood-Evans; Sauveur-Michel Maira; Georg Martiny-Baron; Christian R Schnell; Patrizia Sini; Terence O'Reilly
Journal:  Clin Cancer Res       Date:  2009-02-17       Impact factor: 12.531

8.  Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Roberto Pili; Georg A Bjarnason; Xavier Garcia-del-Muro; Jeffrey A Sosman; Ewa Solska; George Wilding; John A Thompson; Sindy T Kim; Isan Chen; Xin Huang; Robert A Figlin
Journal:  J Clin Oncol       Date:  2009-06-01       Impact factor: 44.544

9.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

Authors:  Robert J Motzer; Bernard Escudier; Stéphane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Gladys Urbanowitz; William J Berg; Andrea Kay; David Lebwohl; Alain Ravaud
Journal:  Lancet       Date:  2008-07-22       Impact factor: 79.321
  9 in total
  26 in total

1.  A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study.

Authors:  Warren P Mason; Mary Macneil; Petr Kavan; Jacob Easaw; David Macdonald; Brian Thiessen; Shweta Urva; Zarnie Lwin; Lynn McIntosh; Elizabeth Eisenhauer
Journal:  Invest New Drugs       Date:  2011-12-09       Impact factor: 3.850

2.  Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination.

Authors:  Fumiko Taguchi; Yasuo Kodera; Yasufumi Katanasaka; Kazuyoshi Yanagihara; Tomohide Tamura; Fumiaki Koizumi
Journal:  Invest New Drugs       Date:  2010-06-08       Impact factor: 3.850

Review 3.  Tailoring mTOR-based therapy: molecular evidence and clinical challenges.

Authors:  Gaetano Santulli; Hana Totary-Jain
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

4.  Monitoring molecular-specific pharmacodynamics of rapamycin in vivo with inducible Gal4->Fluc transgenic reporter mice.

Authors:  Mei-Hsiu Pan; Jeffrey Lin; Julie L Prior; David Piwnica-Worms
Journal:  Mol Cancer Ther       Date:  2010-09-21       Impact factor: 6.261

Review 5.  Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives.

Authors:  Michael W Ronellenfitsch; Joachim P Steinbach; Wolfgang Wick
Journal:  Target Oncol       Date:  2010-09-19       Impact factor: 4.493

6.  Metastatic Renal Cancer: What Role for Everolimus?

Authors:  Franck A Belibi; Charles L Edelstein
Journal:  Clin Med Rev Oncol       Date:  2010-02-18

7.  Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.

Authors:  Dipti K Pawaskar; Robert M Straubinger; Gerald J Fetterly; Bonnie H Hylander; Elizabeth A Repasky; Wen W Ma; William J Jusko
Journal:  Cancer Chemother Pharmacol       Date:  2013-03-03       Impact factor: 3.333

8.  Targeting angiogenesis in metastatic breast cancer.

Authors:  Sangeetha Reddy; Michael Raffin; Virginia Kaklamani
Journal:  Oncologist       Date:  2012-07-27

9.  High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.

Authors:  Lesley A Mathews Griner; Rajarshi Guha; Paul Shinn; Ryan M Young; Jonathan M Keller; Dongbo Liu; Ian S Goldlust; Adam Yasgar; Crystal McKnight; Matthew B Boxer; Damien Y Duveau; Jian-Kang Jiang; Sam Michael; Tim Mierzwa; Wenwei Huang; Martin J Walsh; Bryan T Mott; Paresma Patel; William Leister; David J Maloney; Christopher A Leclair; Ganesha Rai; Ajit Jadhav; Brian D Peyser; Christopher P Austin; Scott E Martin; Anton Simeonov; Marc Ferrer; Louis M Staudt; Craig J Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

10.  Interactions of everolimus and sorafenib in whole blood lymphocyte proliferation.

Authors:  Dipti K Pawaskar; Robert M Straubinger; Gerald J Fetterly; Wen W Ma; William J Jusko
Journal:  Pharm Res       Date:  2012-11-14       Impact factor: 4.200
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.